Biopharmaceuticals · us
How Two Single-Patient Trials Are Charting a Clinical Path for a Rare Genetic Disease
Precision antisense drugs targeting SCN2A have delivered more than reduced seizure frequency; from identifying the disease-causing copy and administering repeated intrathecal doses to tracking multiple dimensions of function, the treatment experiences of two children also reveal how a “one drug for one patient” approach can undergo scientific and regulatory scrutiny.
For extremely rare genetic diseases, the greatest challenge is often not the absence of an identifiable cause, but that there are too few patients to recruit dozens or hundreds of participants for trials in the traditional way. Two children with severe SCN2A encephalopathy have now each received an antisense oligonucleotide (ASO) designed specifically for their own mutation. The results suggest that customized drug development may offer a clinical path, but every step must balance the urgency of treatment against limited evidence.
These two parallel single-patient trials began when the children were 9 and 14 years old, respectively. The research team created a different “allele-selective” ASO for each child, designed to identify and suppress SCN2A messenger RNA carrying the disease-causing mutation while preserving as much of the normal gene copy’s function as possible. The drugs were injected into the cerebrospinal fluid every two to three months, allowing the molecules to reach the central nervous system.
SCN2A produces an important component of neuronal sodium channels; certain gain-of-function mutations cause excessive neuronal excitability, leading to frequent seizures beginning in early childhood and severe developmental impairment. The researchers’ strategy was not to shut down SCN2A entirely, but to reduce the message produced by the mutated copy without also sacrificing the healthy copy. This precise selectivity is the scientific core of the therapy and the reason the drug must be redesigned for each individual sequence.
After more than two years of treatment, seizure frequency in the two children fell by 26% and 90%, respectively, and they were able to reduce or discontinue some antiseizure medications. The research team also documented improvements in language, movement, sensory processing, and everyday adaptive functioning; the older child was able to walk independently for the first time at age 15. The n-Lorem Foundation also said that one patient’s gastrointestinal function improved. These functional changes are encouraging, but some measures relied on caregiver records, and the magnitude of improvement was not consistent between the two patients, so the findings cannot be used to infer that other patients with SCN2A will experience the same results.
Regarding safety, no ASO-related adverse events or serious adverse events were reported during the study period, and laboratory tests, electrocardiograms, and electroencephalograms remained stable. However, follow-up in both patients is still too short to rule out long-term or rare risks. The burden of repeated intrathecal injections, as well as the resources required for the ongoing manufacture, quality control, and monitoring of personalized drugs, will also affect whether this model can be scaled.
One of the studies has been registered as an open-label, single-arm Phase I/II trial, with prespecified measures of seizure frequency, movement, gastrointestinal function, and neurodevelopment over 24 months. This makes the “one drug for one patient” approach more than compassionate use: it is an attempt to build reviewable evidence using endpoints defined in advance. However, the absence of a control group, wide variation in the disease’s natural course, and concurrent adjustments to the participants’ other medications still limit causal conclusions. These two cases therefore represent the beginning of a method and a demonstration of feasibility, rather than an endpoint at which efficacy has been broadly established.